The Israeli biomed sector in 2024 – Yifat Tzafrir in an article at “Globes”

Israeli biomed companies enter 2024 with numerous challenges and uncertainties.

Will FDA approvals translate to an increase in stocks? How will the Gaza war and elections in the U.S. impact them? And which companies are worth following?

Yifat Tzafrir, partner in the commercial law department specializing in the biomed and venture capital sector, in a special article at “Globes”.

Click here for the full article (Hebrew).